Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Nov 1;181(11):1530-1533.
doi: 10.1001/jamainternmed.2021.3779.

Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose

Matthew S Krantz  1 , Jason H Kwah  2 , Cosby A Stone Jr  1 , Elizabeth J Phillips  3   4 , Gilbert Ortega  5 , Aleena Banerji  6   7 , Kimberly G Blumenthal  6   7   8   9
Affiliations
Multicenter Study

Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose

Matthew S Krantz et al. JAMA Intern Med. .

Abstract

This case series study examines the safety of second doses of messenger RNA COVID-19 vaccines after first-dose allergic reactions.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Stone reported grants from the Agency for Healthcare Research and Quality (AHRQ) during the conduct of the study. Dr Phillips reported personal fees from Janssen, Biocyst, Regeneron, Vertex, and UpToDate and grants from the National Institutes of Health (NIH) and grants from NHMRC Australia Monies to institution outside the submitted work. Dr Blumenthal reported grants from NIH/National Institute of Allergy and Infectious Diseases during the conduct of the study. No other disclosures were reported.

Comment in

References

    1. Blumenthal KG, Robinson LB, Camargo CA Jr, et al. . Acute allergic reactions to mRNA COVID-19 vaccines JAMA. 2021;325(15):1562-1565. doi:10.1001/jama.2021.3976 - DOI - PMC - PubMed
    1. US Centers for Disease and Control Prevention . Interim clinical considerations for use of mRNA COVID-19 vaccines. Accessed May 17, 2021. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considera...)
    1. Banerji A, Wickner PG, Saff R, et al. . mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9(4):1423-1437. doi:10.1016/j.jaip.2020.12.047 - DOI - PMC - PubMed
    1. Rüggeberg JU, Gold MS, Bayas JM, et al. ; Brighton Collaboration Anaphylaxis Working Group . Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5675-5684. doi:10.1016/j.vaccine.2007.02.064 - DOI - PubMed
    1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. . Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391-397. doi:10.1016/j.jaci.2005.12.1303 - DOI - PubMed

Publication types